We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Longitudinal Laboratory Data Predicts Complication in Crohn’s Disease Patients

By LabMedica International staff writers
Posted on 27 Sep 2022

Stenosis, fistulization, and perforation of the bowel are severe outcomes which can occur in patients with Crohn’s disease. More...

Accurate prediction of these events may enable clinicians to alter treatment strategies and avoid these outcomes.

Crohn’s disease is a chronic inflammatory condition of the human gastrointestinal tract of undetermined etiology. It is characterized by a relapsing and remitting course and by significant morbidity from chronic abdominal pain, diarrhea, and perianal abscesses.

Gastroenterologists at the Royal Brisbane and Women’s Hospital (Brisbane, Australia) and their colleagues studied the correlation between longitudinal laboratory testing and subsequent intestinal complications in 246 patients with Crohn’s disease. This was an observational cohort of patients with Crohn’s disease at a single center were analyzed between 01/01/1994 and 06/30/2016. A complication was defined as the development of an intestinal fistula, stenosis, or perforation.

The team analyzed C-reactive protein (CRP, (mg/L), erythrocyte sedimentation rate (ESR, mm/h), hemoglobin level (g/L), mean cell volume (MCV, fL), white blood cell count (WCC, × 109/L), platelet count (× 109/L), neutrophil count (× 109/L), fecal calprotectin (mcg/g feces), ferritin (mcg/L), alanine transferase (ALT, IU/L), and albumin (g/L).

The scientists reported that n 246 patients they observed over a median of 5.72 years, 134 complications occurred. Minimum or maximum value in a preceding window period of one year was most strongly associated with subsequent complication. A Longitudinal Laboratory score of ≥ 2 (maximum albumin level < 39 g/L = 1, maximum mean cell volume < 88 fL = 1, minimum platelet count > 355 × 109/L = 1, minimum C reactive protein > 5 mg/L = 1) was 62% sensitive and 91% specific in identifying patients who develop a subsequent complication. A Longitudinal Laboratory score ≥ 2 predicted the development of a future complication, with a positive predictive value of 84%, and a negative predictive value of 76%.

The authors concluded that consistently reduced serum albumin and MCV, and consistently increased CRP and platelet count are associated with future development of complications in patients with Crohn’s disease. These laboratory changes are observed up to two years prior to the development of a complication. In addition to recognized markers of poor outcome in Crohn’s disease, longitudinal laboratory tests may be assessed and used to provide a rationale for timely escalation of therapy. The study was published on September 20 2022 in the journal Digestive Diseases and Sciences.

Related Links:
Royal Brisbane and Women’s Hospital


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Serological Pipet Controller
PIPETBOY GENIUS
New
Staining Management Software
DakoLink
New
Host Response Immunoassay Test
MeMed BV
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.